REG - Oxford Nanopore Tech - Director Declaration

Oxford Nanopore TechnologiesAnnouncement

09/08/2024 15:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240809:nRSI9586Za&default-theme=true

RNS Number : 9586Z  Oxford Nanopore Technologies plc  09 August 2024

09 August 2024

Oxford Nanopore Technologies plc

Director Declaration

Pursuant to Listing Rule 6.4.9 R(2), Oxford Nanopore Technologies plc (the
"Company") confirms that Heather Preston, Non-Executive Director of the
Company, was appointed to the Board of Aligos Therapeutics (Nasdaq: ALGS) as
Non-Executive Director effective 7 August 2024.

 

 ENDS 

 

For further information, please contact:

Oxford Nanopore Technologies plc

Investors:         ir@nanoporetech.com (mailto:ir@nanoporetech.com)

Media:              media@nanoporetech.com
(mailto:media@nanoporetech.com)

 

Teneo (communications adviser to the Company)

Tom Murray, Olivia Peters

+44 (0) 20 7353 4200

OxfordNanoporeTechnologies@teneo.com
(mailto:OxfordNanoporeTechnologies@teneo.com)

 

About Oxford Nanopore Technologies plc:

Oxford Nanopore Technologies' goal is to bring the widest benefits to society
through enabling the analysis of anything, by anyone, anywhere. The company
has developed a new generation of nanopore-based sensing technology that is
currently used for real-time, high-performance, accessible, and scalable
analysis of DNA and RNA.  The technology is used in more than 120 countries,
to understand the biology of humans, plants, animals, bacteria, viruses and
environments as well as to understand diseases such as cancer. Oxford
Nanopore's technology also has the potential to provide broad, high impact,
rapid insights in a number of areas including healthcare, food and
agriculture.

 

Oxford Nanopore devices sequence DNA and RNA directly and sequence short to
ultra-long fragments of DNA, for a truly comprehensive picture of the genome.
Data is streamed in real-time and can enable rapid insights.  The technology
is fully scalable - from pocket-sized to ultra-high throughput devices.

 

For more information please visit: www.nanoporetech.com
(http://www.nanoporetech.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RDNPLMJTMTAMBII